Drug Trial News

RSS

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

$ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients$

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.

26 May 2016

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Researchers at the University of Southampton are to study the use of Chinese Herbal Medicines in treating recurrent urinary tract infections (RUTIs), in the first clinical trial of its kind in the UK.

25 May 2016

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.

25 May 2016

Aliskiren fails to show benefit for heart failure patients with diabetes

A subgroup analysis in heart failure patients with diabetes from the ATMOSPHERE trial has failed to show benefit and signals the end of the road for aliskiren in heart failure.

24 May 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

High doses of vitamin D supplements could lead to fewer birth complications but reduce fertility

New research has established that high doses of vitamin D supplements can lead to fewer complications during childbirth but reduce a woman's chances of getting pregnant in the first place.

19 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

17 May 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa formulation used in both ND0612H and ND0612L.

13 May 2016

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

13 May 2016

Modified dosage of clot-busting drug can reduce intracerebral haemorrhage

The safety of a controversial clot-busting drug has been investigated by researchers, who have shown a modified dosage can reduce serious bleeding in the brain and improve survival rates.

11 May 2016

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers.

10 May 2016

Experimental vaccine protects healthy U.S. adults from malaria infection for more than one year

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine.

10 May 2016

Study finds no gender-based differences on use of anticoagulation medications in TAVR patients

A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.

9 May 2016

Women often excluded from type 2 diabetes drug trials

While women who are pregnant, or breastfeeding or who may become pregnant are often excluded from clinical trials for type 2 diabetes drugs, the exclusion is frequently not based on the risk of fetal harm, according to Penn State College of Medicine researchers and may be contributing to the underrepresentation of women in clinical trials and an incomplete understanding of the effects of drugs on women who become pregnant unexpectedly.

6 May 2016

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

5 May 2016